ClinicalTrials.Veeva

Menu
E

EP-SOGO Co., Ltd. | Nagoya City University Hospital

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Lenalidomide
Dexamethasone
Daratumumab
Elranatamab
Bortezomib
JNJ-77242113
Pembrolizumab
Pomalidomide
ABBV-383
Upadacitinib

Parent organization

This site is a part of EP-SOGO Co., Ltd.

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

88 of 157 total trials

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Nonsegmental Vitiligo (Active and Stable) Tranquillo

Active, not recruiting
Stable Nonsegmental Vitiligo
Active Nonsegmental Vitiligo
Drug: Ritlecitinib
Drug: Placebo

This study is to evaluate how safe and effective ritlecitinib is in participants with non-segmental vitiligo (NSV).Ritlecitinib is studied in patient...

Enrolling
Vitiligo
Drug: Ritlecitinib
Drug: Ritlecitinib 100 mg
Locations recently updated

Researchers are looking for other ways to treat breast cancer (BC) that is hormone receptor-positive and human epidermal growth factor receptor 2-neg...

Enrolling
Breast Neoplasms
Drug: Paclitaxel
Biological: Patritumab deruxtecan

The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-c...

Enrolling
Multiple Myeloma
Drug: Cilta-cel

The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in...

Enrolling
Metabolic Dysfunction-Associated Steatotic Liver Disease
Drug: Tirzepatide
Drug: Placebo

The goal of this clinical trial is to see how well cenerimod reduces symptoms of Systemic Lupus Erythematosus in adult patients with moderate to seve...

Enrolling
Lupus Erythematosus, Systemic
Drug: Placebo
Drug: Cenerimod

The goal of this clinical trial is to see how well cenerimod reduces symptoms of Systemic Lupus Erythematous in adult patients with moderate to sever...

Enrolling
Lupus Erythematosus, Systemic
Drug: Cenerimod
Drug: Placebo

Age-related macular degeneration (AMD) is an eye disease which causes people to lose their vision over time. AMD damages the macula, which is in the...

Enrolling
Age-Related Macular Degeneration
Geographic Atrophy
Drug: avacincaptad pegol

The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with r...

Enrolling
Multiple Myeloma
Drug: Fludarabine
Drug: Cyclophosphamide

The purpose of this study to determine if the addition of daratumumab to bortezomib + lenalidomide + dexamethasone (VRd) will improve overall minimal...

Active, not recruiting
Multiple Myeloma
Drug: Lenalidomide
Drug: Daratumumab

The purpose of this study is to compare the efficacy of ciltacabtagene autoleucel (cilta-cel) with standard therapy, either Pomalidomide, Bortezomib...

Active, not recruiting
Multiple Myeloma
Drug: Pomalidomide
Drug: Bortezomib
Locations recently updated

The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician...

Enrolling
Metastatic HER2-positive Breast Cancer
Drug: Trastuzumab
Drug: Gemcitabine

The main aim of this study is to assess whether zasocitinib works better than deucravacitinib in treating participants with moderate-to-severe plaque...

Enrolling
Plaque Psoriasis
Drug: Zasocitinib
Drug: Placebo to match zasocitinib

The purpose of this study is to compare the efficacy of Bortezomib, Lenalidomide and Dexamethasone (VRd) induction followed by a single administratio...

Active, not recruiting
Multiple Myeloma
Drug: Lenalidomide
Drug: Bortezomib

The purpose of this study is to evaluate the efficacy and safety of JNJ-78934804 as compared to guselkumab and golimumab in participants with moderat...

Active, not recruiting
Colitis, Ulcerative
Biological: JNJ-78934804
Drug: Placebo

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active ulcerative colitis...

Active, not recruiting
Ulcerative Colitis
Drug: Guselkumab
Drug: Placebo

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cance...

Enrolling
Breast Neoplasms
Drug: Anastrozole
Drug: Tamoxifen

The purpose of this study is to evaluate how effective JNJ-77242113 is in participants with generalized pustular psoriasis (GPP) or erythrodermic pso...

Active, not recruiting
Generalized Pustular Psoriasis
Erythrodermic Psoriasis
Drug: JNJ-77242113

The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deu...

Active, not recruiting
Plaque Psoriasis
Drug: Deucravacitinib Matching Placebo
Drug: JNJ-77242113 Matching Placebo

The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.

Active, not recruiting
Plaque Psoriasis
Drug: JNJ-77242113
Drug: Placebo

Trial sponsors

Pfizer logo
Janssen (J&J Innovative Medicine) logo
AbbVie logo
Celgene logo
Merck Sharp & Dohme (MSD) logo
Lilly logo
Janssen (J&J Innovative Medicine) logo
Takeda logo
Amgen logo
Bayer logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems